EGFR antibody (PerCP-Cy5.5)

Catalog No. ABIN2660177

The Mouse Monoclonal anti-EGFR antibody is suitable to detect EGFR in samples from Human. It has been validated for IHC, IF and FACS.

Quick Overview for EGFR antibody (PerCP-Cy5.5) (ABIN2660177)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EGFR antibody is conjugated to PerCP-Cy5.5

Application: Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Clone: AY13

Product Details anti-EGFR Antibody (PerCP-Cy5.5)

Purification: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Alternative Name: EGFR

Background: Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and member of the protein kinase superfamily that regulates cell growth and differentiation. EGFR binds EGF, TGF-α, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor - all members of the EGF family. Ligand binding induces EGFR dimerization and autophosphorylation, initiating the MAPK, Akt, and JNK signaling pathways. EGFR is expressed by epithelial and endothelial cells and is frequently expressed by epithelial carcinomas.

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins